289 related articles for article (PubMed ID: 22073820)
1. What does the dialysate level of matrix metalloproteinase 2 tell us?
Ertilav M; Timur O; Hür E; Bozkurt D; Nar H; Kologlu T; Sen S; Duman S
Adv Perit Dial; 2011; 27():6-10. PubMed ID: 22073820
[TBL] [Abstract][Full Text] [Related]
2. Peritoneal effluent MMP-2 and PAI-1 in encapsulating peritoneal sclerosis.
Lopes Barreto D; Struijk DG; Krediet RT
Am J Kidney Dis; 2015 May; 65(5):748-53. PubMed ID: 25530106
[TBL] [Abstract][Full Text] [Related]
3. The potential of matrix metalloproteinase-2 as a marker of peritoneal injury, increased solute transport, or progression to encapsulating peritoneal sclerosis during peritoneal dialysis--a multicentre study in Japan.
Hirahara I; Inoue M; Okuda K; Ando Y; Muto S; Kusano E
Nephrol Dial Transplant; 2007 Feb; 22(2):560-7. PubMed ID: 17035369
[TBL] [Abstract][Full Text] [Related]
4. Matrix metalloproteinase levels in the drained dialysate reflect the peritoneal solute transport rate: a multicentre study in Japan.
Hirahara I; Inoue M; Umino T; Saito O; Muto S; Kusano E
Nephrol Dial Transplant; 2011 May; 26(5):1695-701. PubMed ID: 20921293
[TBL] [Abstract][Full Text] [Related]
5. Pioglitazone reduces peritoneal fibrosis via inhibition of TGF-β, MMP-2, and MMP-9 in a model of encapsulating peritoneal sclerosis.
Saglam F; Cavdar Z; Sarioglu S; Kolatan E; Oktay G; Yilmaz O; Camsari T
Ren Fail; 2012; 34(1):95-102. PubMed ID: 22136281
[TBL] [Abstract][Full Text] [Related]
6. Encapsulating peritoneal sclerosis: what have we learned?
Goodlad C; Brown EA
Semin Nephrol; 2011 Mar; 31(2):183-98. PubMed ID: 21439432
[TBL] [Abstract][Full Text] [Related]
7. Oral supplementation with sulodexide inhibits neo-angiogenesis in a rat model of peritoneal perfusion.
Pletinck A; Van Landschoot M; Steppan S; Laukens D; Passlick-Deetjen J; Vanholder R; Van Biesen W
Nephrol Dial Transplant; 2012 Feb; 27(2):548-56. PubMed ID: 21750165
[TBL] [Abstract][Full Text] [Related]
8. Effects of low glucose degradation products peritoneal dialysis fluid on the peritoneal fibrosis and vascularization in a chronic rat model.
Kim CD; Kwon HM; Park SH; Oh EJ; Kim MH; Choi SY; Choi MJ; Kim IS; Park MS; Kim YJ; Kim YL
Ther Apher Dial; 2007 Feb; 11(1):56-64. PubMed ID: 17309576
[TBL] [Abstract][Full Text] [Related]
9. Octreotide lessens peritoneal injury in experimental encapsulated peritoneal sclerosis model.
Ertilav M; Hur E; Bozkurt D; Sipahi S; Timur O; Sarsik B; Akcicek F; Duman S
Nephrology (Carlton); 2011 Aug; 16(6):552-7. PubMed ID: 21382127
[TBL] [Abstract][Full Text] [Related]
10. Peritoneal dialysis patients with high effluent fibrin degradation products.
Moriishi M; Kawanishi H; Tsuchiya S
Adv Perit Dial; 2009; 25():41-4. PubMed ID: 19886315
[TBL] [Abstract][Full Text] [Related]
11. Epithelial-to-mesenchymal transdifferentiation of peritoneal mesothelial cells mediated by oxidative stress in peritoneal fibrosis rats.
Duan S; Yu J; Liu Q; Wang Y; Pan P; Xiao L; Ling G; Liu F
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2011 Jan; 36(1):34-43. PubMed ID: 21311137
[TBL] [Abstract][Full Text] [Related]
12. MicroRNAs in peritoneal dialysis effluent are promising biomarkers for peritoneal fibrosis in peritoneal dialysis patients.
Ge Y; Xiao L; Chen X; Peng Y; Sun L; Liu F
Med Hypotheses; 2012 Jan; 78(1):155-6. PubMed ID: 22056978
[TBL] [Abstract][Full Text] [Related]
13. Rosiglitazone, a peroxisome proliferator-activated receptor agonist, improves peritoneal alterations resulting from an encapsulated peritoneal sclerosis model.
Bozkurt D; Taskin H; Sezak M; Biçak S; Sen S; Ok E; Duman S
Adv Perit Dial; 2008; 24():32-8. PubMed ID: 18985998
[TBL] [Abstract][Full Text] [Related]
14. Effects of everolimus as an antiproliferative agent on regression of encapsulating peritoneal sclerosis in a rat model.
Duman S; Bozkurt D; Sipahi S; Sezak M; Ozkan S; Ertilav M; Sen S; Ok E
Adv Perit Dial; 2008; 24():104-10. PubMed ID: 18986012
[TBL] [Abstract][Full Text] [Related]
15. Calcitriol decreases TGF-β1 and angiotensin II production and protects against chlorhexide digluconate-induced liver peritoneal fibrosis in rats.
Lee CJ; Subeq YM; Lee RP; Liou HH; Hsu BG
Cytokine; 2014 Jan; 65(1):105-18. PubMed ID: 24210651
[TBL] [Abstract][Full Text] [Related]
16. Effects of atorvastatin on development of peritoneal fibrosis in rats on peritoneal dialysis.
Yeniçerioglu Y; Uzelce O; Akar H; Kolatan E; Yilmaz O; Yenisey C; Sarioglu S; Meteoglu I
Ren Fail; 2010; 32(9):1095-102. PubMed ID: 20863215
[TBL] [Abstract][Full Text] [Related]
17. The effect of oxidative stress inhibition with trimetazidine on the peritoneal alterations induced by hypertonic peritoneal dialysis solution.
Günal AI; Celiker H; Ustundag B; Akpolat N; Dogukan A; Akcicek F
J Nephrol; 2003; 16(2):225-30. PubMed ID: 12768069
[TBL] [Abstract][Full Text] [Related]
18. Glucocorticoid protects against the development of encapsulating peritoneal sclerosis on peritoneal dialysis.
Imai H; Nakamoto H; Fucshima R; Yamanouchi Y; Ishida Y; Suzuki H
Adv Perit Dial; 2002; 18():124-30. PubMed ID: 12402603
[TBL] [Abstract][Full Text] [Related]
19. Role of adhesion molecules in the progression of peritoneal sclerosis.
Imai H; Nakamoto H; Fukushima R; Ishida Y; Yamanouchi Y; Suzuki H
Adv Perit Dial; 2003; 19():180-5. PubMed ID: 14763058
[TBL] [Abstract][Full Text] [Related]
20. Activation of matrix metalloproteinase-2 causes peritoneal injury during peritoneal dialysis in rats.
Hirahara I; Ogawa Y; Kusano E; Asano Y
Nephrol Dial Transplant; 2004 Jul; 19(7):1732-41. PubMed ID: 15128883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
